| abstract |
[Problem]nThe purpose of the present invention is to provide a pharmaceutical preparation for preventing and/or treating various diseases, which comprises a compound capable of increasing a translation initiation factor or a transcription elongation factor or a pharmaceutically acceptable salt thereof as an active ingredient.n[Solution]nThe present inventors made extensive studies for the purpose of solving the problem, and it is found for the first time that the increase in a translation initiation factor (e.g., eIF4A1) or a translation elongation factor (e.g., eEF1A1) is involved in the NGF-induced neurite elongation potentiating activity of minocycline or cilostazol, and the invention has been accomplished. |